详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic target

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [4]Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

出处：

DOI：

ISSN：

关键词： ILF2 NF45 cancer prognosis biomarkers nuclear protein

摘要：

Interleukin enhancer binding factor 2 (ILF2), formerly called nuclear factor 45 (NF45), is widely expressed in normal human tissues. ILF2 often binds to interleukin enhancer binding factor 3 (ILF3) and regulates gene expression in several ways, participating in multiple DNA and RNA metabolism pathways. Recent studies have shown that ILF2 expression is significantly upregulated in esophageal cancer, lung cancer, gastric cancer, and other malignant tumors, which can promote tumor development and tumor cell proliferation, affect the cell cycle, and induce epithelial-mesenchymal transition. ILF2 expression is closely related to tumor cell migration and invasion, neo-angiogenesis, and patient prognosis. ILF2 is expected to become a biomarker for the early diagnosis of patients with tumors and assessing their prognosis. This article reviews the role of ILF2 in malignant tumors and its related mechanisms.Copyright © 2024 Sun, Li, Zhang, Zou and Zhang.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Lost or Forgotten: The nuclear cathepsin protein isoforms in cancer. [2]Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. [3]Role of Numb expression and nuclear translocation in endometrial cancer. [4]Multi-omics analysis reveals inflammatory biomarkers for skin melanoma prognosis [5]Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer [6]Unlocking the potential of oncology biomarkers: advancements in clinical theranostics [7]A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer [8]Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer [9]FJX1 as a candidate diagnostic and prognostic serum biomarker for colorectal cancer. [10]Trichodimerol inhibits inflammation through suppression of the nuclear transcription factor-kappaB/NOD-like receptor thermal protein domain associated protein 3 signaling pathway